|
Objective To observe the human epidermal growth factor receptor 4 (ErbB4) expression and phosphorylation changes in diabetic rat heart, explore of ErbB4 receptor with diabetic cardiomyopathy Contact. Methods 36 8-week-old male SD rats were divided into four groups: the four weeks control group (n = 6), 4-week diabetic group (n = 12), 12 weeks the control group (n = 6) and 12 weeks diabetic group (n = 12), intraperitoneal injection of streptozotocin (Streptozotocin, STZ) diabetic model (55mg/kg). Detecting cardiac function using echocardiography, rat body weight was measured using an electronic balance, heart mass and calculated heart weight / body weight (HW / BW), hematoxylin - eosin staining rat cardiac tissue structures and lesions, collagen the fibers staining. myocardial interstitial fibrosis, glycogen staining observed degree of myocardial glycogen deposition, determination of left ventricular myocardial ErbB4 mRNA levels by real-time polymerase chain reaction, Western blot detection rats left The ventricular myocardium phosphorylated ErbB4 level. Results at 4 weeks compared with the control group, diabetic group left ventricular fractional shortening reduce (45.2% ± 4.79% vs. 52.3% ± 4.50%, P lt; 0.05), a decrease in heart rate [(333 ± 34.3) times / min significant fibrosis (4.48% ± 0.21% vs. 2.79% ± 0.36%, P lt; 0.01), myocardial glycogen deposition significantly (2.66% ± 0.34% vs. 1.72% ± 0.33, P lt; 0.01); 12 weeks Compared with the control group, diabetes group, left ventricular end systolic diameter increased [(3.57 ± 0.232) mm vs (3.06 ± 0.376) mm, P lt; 0.05] significantly decreased left ventricular ejection fraction (72.5% ± 3.81% vs. 82.6% ± 2.97%, P lt; 0.01), left ventricular fractional shortening was significantly reduced (41.1% ± 3.91% vs 52.3% ± 8.37%, P lt; 0.05), heart rate significantly lower (212 ± 16.7 ) / min vs. (391 ± 47.9) beats / min, P lt; 0.01] HW / BW was significantly higher [(3.72 ± 0.38) mg / g vs (2.39 ± 0.26) mg / g, P lt; 0.01 0.01), left ventricular myocardial ErbB4 mRNA expression was significantly decreased by (0.51 ± 0.16 vs. 0.99 ± 0.17, P lt; 0.01), left ventricular myocardial phosphorylation ErbB4 also significantly reduced (0.931 ± 0.016 vs. 1.012 ± 0.011 , P lt; 0.01). Correlation analysis showed that the left ventricular ejection fraction and myocardial interstitial fibrosis, myocardial glycogen deposition was a significant negative correlation (r 1 = -0.804, P lt; 0.01; r2 = -0.803, P lt ; 0.01), and myocardial the ErbB4 the mRNA expression levels, myocardial phosphorylated ErbB4 was a significant positive correlation (r 3 = 0.666, P lt; 0.01; r 4 = 0.754, P lt; 0.01); left ventricular shortening fraction and myocardial interstitial fibrosis, myocardial glycogen deposition was a significant negative correlation (r = -0.590, P lt; 0.01; r 6 = -0.565, P lt; 0.01), and myocardial the ErbB4 the mRNA expression levels, myocardial phosphorylation ErbB4 was a significant positive correlation (r 7 = 0.480, P lt; 0.05; r 8 = 0.553, P lt; 0.01). Diabetic rat model, conclusions STZ injection manufacturing heart function at 12 weeks significantly decreased myocardial hypertrophy, significant myocardial interstitial fibrosis, myocardial glycogen deposition, in line with the characteristics of diabetic cardiomyopathy. Increased myocardial interstitial fibrosis and myocardial glycogen deposition decreased heart function, reduced ErbB4 receptor expression and phosphorylation of ErbB4. ErbB4 expression The reduce and ErbB4 signal transduction weakened may be involved in the pathogenesis of diabetic rats cardiomyopathy.
|